Products
Tafamidis was approved in the EU in 2011, in the US in 2019, and in many countries in 2020 in soft capsule form (Vyndaqel).
Structure and properties
Tafamidis (C14H7Cl2NO3, Mr = 308.1 g/mol) is present in the drug either as tafamidis meglumine or as tafamidis.
Effects
Tafamidis (ATC N07XX08) is a selective stabilizer of transthyretin (TTR). It binds to thyroxine binding sites, stabilizing the tetramer and slowing its cleavage into monomers. The mean half-life is approximately 49 hours.
Indications
- For the treatment of transthyretin amyloidosis in adult patients with wild-type or hereditary cardiomyopathy to reduce all-cause mortality and cardiovascular-related hospitalization.
Additional indication in Europe:
- For the treatment of transthyretin amyloidosis in adult patients with symptomatic stage 1 polyneuropathy to delay the decline in peripheral neurological function.
Dosage
According to the professional information. The capsules are taken once a day, regardless of meals.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Adverse effects
Possible adverse effects include:
- Urinary tract infections
- Vaginal infections
- Diarrhea
- Upper abdominal pain
